Evidence map›Paper›PMID 40447716›Full record

ArticleCommunications medicine2025

International importance and spread of SARS-CoV-2 variants Alpha, Delta, and Omicron BA.1 into Spain.

Pilar Gallego-García, Samuel L Hong, Nena Bollen, Simon Dellicour, Guy Baele, Marc A Suchard, Philippe Lemey, David Posada

Abstract read
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Pilar Gallego-GarcíaCINBIO, Universidade de Vigo, Vigo, 36310, Spain.
Samuel L HongDepartment of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0001-6354-4943
Nena BollenDepartment of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000, Leuven, Belgium.
Simon DellicourDepartment of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000, Leuven, Belgium.
Guy BaeleDepartment of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0002-1915-7732
Marc A SuchardDepartment of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0001-9818-479X
Philippe LemeyDepartment of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0003-2826-5353
David PosadaCINBIO, Universidade de Vigo, Vigo, 36310, Spain. dposada@uvigo.gal.ORCID http://orcid.org/0000-0003-1407-3406

Funding

Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Laura D. Hughes · 2018 to 2026
$32.0M
Fast and flexible Bayesian phylogenetics via modern machine learningR01AI162611 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MATSEN, FREDERICK ALBERT · 2021 to 2025
$3.8M
Statistical Innovation to Integrate Sequences and Phenotypes for Scalable Phylodynamic InferenceR01AI153044 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Marc A. Suchard · 2021 to 2026
$2.4M
Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia (Ministry of Culture, Education and University Planning, Government of Galicia) ED481A-2021/345EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 725422EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 874850Fonds De La Recherche Scientifique - FNRS (Belgian National Fund for Scientific Research) F.4515.22Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G051322NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G098321NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G0D5117NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G0E1420NKU Leuven (Katholieke Universiteit Leuven) C14/18/094NIAID NIH HHS R01 AI153044NIAID NIH HHS R01 AI162611NIAID NIH HHS U19 AI135995Wellcome TrustWellcome Trust (Wellcome) 206298/Z/17/Z
6 · The paper itself

Abstract

backgroundThe spread of SARS-CoV-2 has been influenced by multiple factors, from the inherent transmission capabilities of the different variants to the control measurements put in place. Understanding how new variants enter a country is essential for managing future outbreaks. This study investigates how three major variants-Alpha, Delta, and Omicron (BA.1)-entered Spain and how different restrictions potentially affected their introduction.

methodsWe collected Spanish and international SARS-CoV-2 genomes from the GISAID database. Leveraging connectivity data from different countries with Spain, we performed a phylodynamic Bayesian analysis of the SARS-CoV-2 introductions into Spain.

resultsMost introductions of the Alpha variant originated from France. As travel restrictions eased, the number of introductions from different countries increased. During the Delta and Omicron waves, the United Kingdom and Germany became important sources of the virus. The highest number of introductions occurred during the Delta wave, coinciding with fewer travel restrictions and the summer season, when Spain receives a considerable number of tourists.

conclusionsOur findings highlight the role of international travel in the spread of new variants. They underscore the importance of monitoring travel patterns and implementing targeted public health measures to manage the spread of SARS-CoV-2.

Identifiers

PMID40447716
PMCPMC12125294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.